IL15 and neoplasm: Localized delivery of eSTING and IL-15/IL-15Rα via ACTM-838 exhibits effective synergistic activity to engage both innate and adaptive immunity in the tumor and generate a durable T-cell mediated systemic anti-tumor immune response.